Who are Placebo matching with Sitagliptin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Tang, Galvus (vildagliptin), Vildagliptin (LAF237), Vildagliptin (Galvus), CSII+Vildagliptin, Metformin / alogliptin Oral Product.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/placebo-matching-with-sitagliptin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Placebo matching with Sitagliptin — Competitive Intelligence Brief

Placebo matching with Sitagliptin (Placebo matching with Sitagliptin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: DPP-4 inhibitor. Area: Diabetes.

phase 3 DPP-4 inhibitor DPP-4 (Dipeptidyl peptidase-4) Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

Placebo matching with Sitagliptin (Placebo matching with Sitagliptin) — AstraZeneca. Sitagliptin inhibits dipeptidyl peptidase-4 (DPP-4) to increase levels of incretin hormones, which stimulate insulin secretion in response to glucose.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Placebo matching with Sitagliptin TARGET	Placebo matching with Sitagliptin	AstraZeneca	phase 3	DPP-4 inhibitor	DPP-4 (Dipeptidyl peptidase-4)
Tang	Tang	Louisville Metabolic and Atherosclerosis Research Center	marketed	DPP-4 inhibitor	DPP-4
Galvus (vildagliptin)	Galvus (vildagliptin)	Korea University Anam Hospital	marketed	DPP-4 inhibitor	DPP-4 (dipeptidyl peptidase-4)
Vildagliptin (LAF237)	Vildagliptin (LAF237)	Novartis	marketed	DPP-4 inhibitor	DPP-4 (dipeptidyl peptidase-4)
Vildagliptin (Galvus)	Vildagliptin (Galvus)	University Hospital, Strasbourg, France	marketed	DPP-4 inhibitor	DPP-4 (dipeptidyl peptidase-4)
CSII+Vildagliptin	CSII+Vildagliptin	The First Affiliated Hospital of Xiamen University	marketed	DPP-4 inhibitor (combined with insulin therapy)	DPP-4 (dipeptidyl peptidase-4)
Metformin / alogliptin Oral Product	Metformin / alogliptin Oral Product	University of Catanzaro	marketed	Biguanide / DPP-4 inhibitor combination	Metformin: mitochondrial glycerophosphate dehydrogenase; Alogliptin: dipeptidyl peptidase-4 (DPP-4)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (DPP-4 inhibitor class)

Merck Sharp & Dohme LLC · 5 drugs in this class
Daewoong Pharmaceutical Co. LTD. · 4 drugs in this class
AstraZeneca · 4 drugs in this class
LG Life Sciences · 2 drugs in this class
Tanabe Pharma Corporation · 2 drugs in this class
Ain Shams University · 2 drugs in this class
Ono Pharmaceutical Co. Ltd · 2 drugs in this class
Cinnagen · 1 drug in this class
GRADE Study Group · 1 drug in this class
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Placebo matching with Sitagliptin — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-matching-with-sitagliptin. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab